Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.76 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.76 |
| ▸ | EGFR | P00533 | 12/20 | 0.74 |
| ▸ | KDR | P35968 | 9/20 | 0.70 |
| ▸ | RET | P07949 | 7/20 | 0.68 |
| ▸ | GAK | O14976 | 3/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.68 |
| ▸ | STK10 | O94804 | 1/20 | 0.68 |
| ▸ | FLT3 | P36888 | 1/20 | 0.68 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.68 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.68 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.68 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.68 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.68 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.68 |
| ▸ | KIF5B | P33176 | 5/20 | 0.67 |
| ▸ | SRC | P12931 | 2/20 | 0.67 |
| ▸ | LCK | P06239 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30925305 | 1.00 | JAK3 (1.00) | JAK3MKNK1ABCG2ABCB1EGFR | |
| SCHEMBL5864733 | 0.88 | JAK3 (0.79) | JAK3MKNK1ABCG2ABCB1EGFR | |
| SCHEMBL29372372 | 0.86 | JAK3 (1.00) | JAK3MKNK1ABCG2ABCB1EGFR | |
| SCHEMBL29651 | 0.86 | JAK3 (1.00) | JAK3MKNK1ABCG2ABCB1EGFR | |
| SCHEMBL29711485 | 0.86 | JAK3 (1.00) | JAK3MKNK1ABCG2ABCB1EGFR | |
| SCHEMBL7119275 | 0.85 | JAK3 (0.74) | JAK3MKNK1ABCG2EGFRKDR | |
| SCHEMBL5570070 | 0.84 | EGFR (0.85) | JAK3MKNK1ABCG2ABCB1EGFR | |
| SCHEMBL5864555 | 0.84 | KDR (0.73) | JAK3MKNK1EGFRKDRRET | |
| SCHEMBL6668470 | 0.84 | JAK3 (0.73) | JAK3MKNK1EGFRKDRRET | |
| SCHEMBL5467825 | 0.82 | EGFR (1.00) | JAK3MKNK1ABCG2ABCB1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 526 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | claimed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | claimed |
| WO-2024124240-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS (US) | 2024-06-13 | — | — | WO | claimed |
| US-20230285401-A1 | Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS LLC (US) | 2023-09-14 | — | — | US | claimed |
| CN-116157131-A | Methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2023-05-23 | — | — | CN | claimed |
| US-20230075368-A1 | IDENTIFICATION OF AN EGFR-BIN3 PATHWAY THAT ACTIVELY SUPPRESSES INVASION AND REDUCES TUMOR SIZE IN GLIOBLASTOMA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-03-09 | — | — | US | claimed |
| EP-4106879-A1 | IDENTIFICATION OF AN EGFR-BIN3 PATHWAY THAT ACTIVELY SUPPRESSES INVASION AND REDUCES TUMOR SIZE IN GLIOBLASTOMA | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-12-28 | — | — | EP | claimed |
| EP-3042903-B1 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD (IN) | 2019-08-14 | — | — | EP | claimed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| US-20010044442-A1 | Dimethoxy quinazolines for treating diabetes | PARKER HUGHES INSTITUTE (US) | 2001-11-22 | — | — | US | claimed |
| US-6313130-B1 | PATHOLOGY WHEREIN MAST CELL ACTIVATION OR DEGRANULATION IS IMPLICATED AND INHIBITION OF MAST CELL ACTIVATION OR DEGRANULATION IS DESIRED BY ADMINISTERING A JAUS KINASE-3 INHIBITOR TO MAMMAL | PARKER HUGHES INSTITUTE | 2001-11-06 | — | — | US | claimed |
| US-6313129-B1 | ADMINISTERING TO A MAMMAL QUINAZOLINE DERIVATIVE FOR THERAPY OF ORGAN TRANSPLANT REJECTION | HUGHES INSTITUTE | 2001-11-06 | — | — | US | claimed |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HUGHES INSTITUTE (US) | 2001-08-23 | — | — | US | claimed |
| US-6258820-B1 | ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2001-07-10 | — | — | US | claimed |
| WO-2001045641-A2 | INHIBITORS OF THROMBIN INDUCED PLATELET AGGREGATION | PARKER HUGHES INSTITUTE (US) | 2001-06-28 | — | — | WO | claimed |
| EP-1105378-A1 | QUINAZOLINE DERIVATIVES | Parker Hughes Institute (US) | 2001-06-13 | — | — | EP | claimed |
| WO-2000056338-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2000056720-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2000010981-A1 | QUINAZOLINE DERIVATIVES | PARKER HUGHES INSTITUTE (US) | 2000-03-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | JAK3 19/4885MKNK1 305/4885ABCG2 4677/4885 |
| US-20010044442-A1 | Dimethoxy quinazolines for treating diabetes | JAK3, JAK1, JAK2 | JAK3 1/4885MKNK1 186/4885ABCG2 3602/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | JAK3 91/4885MKNK1 301/4885ABCG2 4498/4885 |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | JAK3 912/4885MKNK1 212/4885ABCG2 401/4885 |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | JAK3 321/4885MKNK1 1914/4885ABCG2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.